A Descriptive Retrospective Database Study to Evaluate Serious Clinical Manifestations and Outcomes among SARS-CoV-2 Diagnosed Patients with RA, PsA or UC treated with systemic therapies: A Post Approval Safety Study of Tofacitinib in the Context of the COVID-19 Pandemic

First published 29/05/2020

Last updated 22/02/2024

EU PAS number:

EUPAS35384

Study

Finalised

Documents

Study protocol

Initial protocol

A3921380_PROTOCOL and APPROVAL_COVID PASS_15May2020

English (2.4 MB - PDF)View document

Updated protocol

A3921380_Protocol Amendment 2 Version 3.0 (clean)_COVID PASS_28 August 2023_Redacted

First published: 22/02/2024

English (3.6 MB - PDF)View document

Study results

A3921380 Non Interventional Study Report Abstract 21 June 2023_Redacted

English (1.27 MB - PDF)View document

Study report

Other information

Study, other information

A3921380 Non Interventional Study Report 11 September 2023_Pages 51-97 Redacted

English (5.34 MB - PDF)View document

A3921380 Non-Interventional Protocol Abstract 12 May 2020

English (1.75 MB - PDF)View document

A3921380_Protocol Amendment 1 (clean)_COVID PASS_20 July 2021

English (2.37 MB - PDF)View document

ENCePP Seal

ENCePP Seal documents

Secondary tabs